Radio Compass Blog | Latest Pharmaceutical Articles

Company Tracker: Promising pipeline to push up AbbVie revenues, despite erosion in Humira sales

Impressions: 754

In our second article of the Company Tracker series, we analyze AbbVie — a company that was spun out of Abbott Laboratories less than a decade ago. This Illinois-headquartered drugmaker holds a lot of promise, and analysts expect it to...

#PharmaFlow by PHARMACOMPASS

01 Dec 2022

Share

CDMO Activity Tracker: Q3 sees increased dealmaking, expansion in CDMO space

Impressions: 1977

Since the start of the pandemic, the pharmaceutical industry has increased its reliance on contract development and manufacturing organizations (CDMOs) to speed up the development of clinical candidates, candidate registration, market authorizatio...

#PharmaFlow by PHARMACOMPASS

17 Nov 2022

Share

Deaths of Gambian children: A wake-up call for drug regulators across the world

Impressions: 1820

News about contamination of cough syrups manufactured by Indian drugmaker Maiden Pharmaceuticals has shaken the global drug industry. According to the statement issued by the World Health Organization (WHO) last week, contaminated cough and cold ...

#PharmaFlow by PHARMACOMPASS

12 Oct 2022

Share

Neurology Newsmakers: Big pharma forges deals to find cures for CNS disorders

Impressions: 2000

This week, we look at the global market for neurological disorder drugs, which has been growing at a healthy rate of 5.9 percent per annum. There are several kinds of neurology disorders, such as epilepsy, Alzheimer’s disease, Parkinson’s...

#PharmaFlow by PHARMACOMPASS

29 Sep 2022

Share

FDA braces for user fee reauthorization delay even as DMF submissions rise in H1 2022

Impressions: 2121

Though the year 2021 was eclipsed by the Covid-19 pandemic, there was no let up in the speed at which generic active pharmaceutical ingredient (API) manufacturers were submitting drug master files (DMFs) to the US Food and Drug Administration (FDA...

#PharmaFlow by PHARMACOMPASS

22 Sep 2022

Share

Company Tracker: Novartis’ robust pipeline, new technology platforms hold promise

Impressions: 2581

Swiss-drug major Novartis has been trying to reinvent itself for nearly a decade, a process that was started by its erstwhile CEO Joseph Jimenez, who passed the baton to Vasant Narasimhan in February 2019, along with the same mandate. Over the la...

#PharmaFlow by PHARMACOMPASS

01 Sep 2022

Share

CDMO Activity Tracker: Q2 sees more deals, partnerships, M&As and expansions

Impressions: 3514

In April this year, our CDMO Activity Tracker had highlighted the favorable trends in the US$ 183.62 billion contract development and manufacturing organizations market. Over the second quarter, we saw those trends continue as the pharmaceutical in...

#PharmaFlow by PHARMACOMPASS

04 Aug 2022

Share

New Drug Approvals by FDA, EMA, Health Canada in first half of 2022

Impressions: 3583

During 2021, regulatory agencies faced a lot of challenges due to the pandemic as they were not able to conduct onsite inspections. As a result, there was a six percent drop in new drug approvals — in both new molecular entities (NMEs) under ne...

#PharmaFlow by PHARMACOMPASS

28 Jul 2022

Share

FDA’s list of off-patent, off-exclusivity drugs sees steep rise in new drug applications

Impressions: 2301

This week, PharmaCompass brings you the key highlights of the US Food and Drug Administration’s June 2022 list of Off-Patent, Off-Exclusivity (OPOE) Drugs with No Approved Generics. The OPOE list gets updated every six months. Since 2...

#PharmaFlow by PHARMACOMPASS

21 Jul 2022

Share

Biosynthesis, tech advancements trigger high growth in medical cannabinoids

Impressions: 2639

Cannabis has been used to treat pain and other ailments since time immemorial, albeit not without controversies over the legal, ethical and societal implications of its use. Cannabinoids, or naturally occurring compounds found in the Cannabis sat...

#PharmaFlow by PHARMACOMPASS

07 Jul 2022

Share

Find the Radio Compass Blog of latest pharmaceutical industry information on PharmaCompass.com

Data Compilation & Company Tracker #PharmaFlow

Company Tracker: Promising pipeline to push up AbbVie revenues, despite erosion in Humira sales

CDMO Activity Tracker: Q3 sees increased dealmaking, expansion in CDMO space

Deaths of Gambian children: A wake-up call for drug regulators across the world

Neurology Newsmakers: Big pharma forges deals to find cures for CNS disorders

FDA braces for user fee reauthorization delay even as DMF submissions rise in H1 2022

Company Tracker: Novartis’ robust pipeline, new technology platforms hold promise

CDMO Activity Tracker: Q2 sees more deals, partnerships, M&As and expansions

New Drug Approvals by FDA, EMA, Health Canada in first half of 2022

FDA’s list of off-patent, off-exclusivity drugs sees steep rise in new drug applications

Biosynthesis, tech advancements trigger high growth in medical cannabinoids